Compare Emerson Electric Co. (EMR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs Natera Inc. Common Stock — how do they compare? Emerson Electric Co. trades at $160.9 (market cap $91.20B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Emerson Electric Co. is the larger of the two by market cap, and Emerson Electric Co. pays a 1.36% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and Natera Inc. Common Stock for 0 Days on average.
| EMR | NTRA | |
|---|---|---|
Market Cap | $91.20B | $57.03B |
Volume | 2,131,741 | 1,131,157 |
Sector | Industrials | Health |
52-Week High | $164.38 | $425.64 |
52-Week Low | $123.30 | $179.42 |
Typical Hold Time | 81 Days | 0 Days |
Enterprise Value | $102.28B | $56.18B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $161.08, down 0.85% on the day, with a bullish technical signal from moving averages. The company shows solid fundamentals with a 13.83% net income margin and consistent earnings beats in recent quarters. Revenue is projected to grow to $18.6B in 2026, and analysts maintain a consensus buy rating with a $165.90 price target, suggesting modest upside. A dividend of $0.56 per share is scheduled for payment in September 2026.
EMR presents a favorable outlook supported by earnings momentum and analyst optimism, though valuation multiples like a P/E of 35.78 are elevated. Key risks include competitive pressures and macroeconomic sensitivity. The stock's proximity to resistance at $164 may prompt near-term consolidation, but fundamental strength supports long-term growth potential.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
